Isomorphic Labs, an AI-first drug design company, has raised a record $2.1 billion Series B round. This is part of a broader trend where AI-focused biotechs have attracted over $6 billion in funding so far in 2026, according to Crunchbase data.
TL;DR
- AI-focused biotechs raised over $6 billion in 2026, with Isomorphic Labs securing the largest round at $2.1 billion.
- Biotech funding remains steady between $36 billion and $40 billion globally, despite the surge in AI investments.
- Early-stage funding dominates the biotech sector, with seed and early-stage rounds comprising over half of all investment.
What happened
In 2026, global biotech startup funding has remained steady, hovering between $36 billion and $40 billion, according to Crunchbase data. This stability is notable amidst the surge in AI investments, which have disrupted funding patterns across other sectors. The first half of 2026 saw record levels of overall venture investment, but much of this was concentrated in a few generative AI behemoths. Biotechs, however, managed to secure a respectable share of the remaining funds.
AI-focused biotechs have been particularly successful in attracting investment. So far this year, these companies have raised over $6 billion. Leading the pack is London-based Isomorphic Labs, which secured a record $2.1 billion Series B round. This makes it the largest round for any biotech this year. Other notable AI biotechs include Earendil Labs, which raised $787 million, and Chai Discovery, which secured $400 million in Series C funding at a $3.8 billion valuation.
Why it matters
For AI/ML developers and startup founders, the steady funding in biotech, especially in AI-focused areas, presents significant opportunities. The intersection of AI and biotech is a growing field with substantial investment potential. Developers with expertise in AI can find valuable applications in drug design, protein therapeutics, and other biotech areas. Startup founders can leverage this trend to attract investment and build innovative solutions at the crossroads of AI and biotech.
For tech investors, the biotech sector offers a stable investment avenue amidst the volatile AI funding landscape. The steady funding levels and the successful exits, including IPOs and M&A transactions, indicate a healthy outlook for the sector. Investors can diversify their portfolios by considering biotech startups, particularly those integrating AI technologies.
Key facts
- Global biotech funding in 2026 is on track to stay between $36 billion and $40 billion, per Crunchbase data.
- AI-focused biotechs have raised over $6 billion in 2026.
- Isomorphic Labs secured a record $2.1 billion Series B round, the largest biotech round this year.
- Earendil Labs raised $787 million in March 2026.
- Chai Discovery secured $400 million in Series C funding at a $3.8 billion valuation.
- Seed and early-stage rounds comprise over half of all biotech investment in 2026.
- At least 12 biotech companies sold in transactions valued at $1 billion or more in 2026.
- Kailera Therapeutics, Kardigan, and Latigo Biotherapeutics are examples of biotechs that went public in 2026.
Context
The biotech sector has historically been a steady area for investment, even as other sectors experience volatility. The integration of AI technologies into biotech has further enhanced its appeal, attracting significant funding and fostering innovation. This trend is expected to continue, with AI-driven biotech solutions likely to play a crucial role in drug discovery, protein therapeutics, and other areas of medical research.
The steady funding and successful exits in the biotech sector underscore its resilience and potential for growth. For developers, founders, and investors, the biotech sector offers a wealth of opportunities to innovate and capitalize on the convergence of AI and biotechnology. As the sector continues to evolve, it will be interesting to see how AI technologies further transform biotech and create new avenues for investment and development.